Jefferies raises Lantheus stock price target on PSMA PET outlook By Investing.com

Jefferies raised its Lantheus (LNTH) price target to $110 from $105 while keeping a Buy rating; the stock trades at $80.08 and analyst targets range $76–$114. Jefferies now models PSMA PET market volume growth of ~20% in 2025 and 10–11% in 2026, and expects commercial rollout of PYL TruVu in Q4 2026 with meaningful contribution in 2027. The FDA approved PYLARIFY TruVu and gave tentative approval for Lutetium Lu 177 Dotatate; Lantheus also reported a Q4 2025 sales and EPS beat and saw multiple competitors/analysts (Citizens $85, Truist $89) raise targets.

Analysis

Lantheus’s upcoming commercial inflection pivots the company from a primarily product-sale cadence toward a mixed model with recurring imaging volume and royalty-like revenue. If execution is tight, the incremental margin on imaging services and downstream supply contracts will compound faster than headline sales because each incremental scan leverages fixed distribution and radiochemistry capacity; conversely, manufacturing bottlenecks or distributor onboarding delays will compress near-term operating leverage and push payor negotiations into the next fiscal year.

Second-order winners include regional nuclear pharmacy networks and hospital outpatient imaging centers that can capture higher throughput and service fees as adoption rises; meanwhile, incumbent radiotherapeutic manufacturers face margin pressure as price competition and channel consolidation accelerate. On the reimbursement front, the path to broad commercial uptake depends more on coding and utilization patterns than on clinical efficacy alone—guideline endorsements or favorable reimbursement decisions could double adoption velocity within 12–24 months, while adverse coding outcomes could stall penetration indefinitely.

Near-term catalysts to watch are commercial roll-out metrics (weekly site activations, dose volumes per site) and cadence of payor sign-ups; these drive realized pricing and therefore EPS revision cycles. Tail risks include supply-chain shocks for isotopes, a faster-than-expected entry of lower-cost generics into key niches, or a dilution event if management accelerates capacity spend; each would materially change the risk/reward profile over 3–18 months.

Key Decisions for Investors

• Long LNTH equity (12-month horizon): allocate 2–4% of portfolio. Expect asymmetric upside if adoption metrics beat, with downside capped by staging a 15–20% stop or trimming into meaningful commercialization news. Rationale: capture margin expansion as utilization scales while keeping position size modest vs execution risk.
• Call-spread (directional, defined-risk): buy a 9–12 month ATM call and sell an OTM call 25–35% higher (use sizes to cap max loss to ~2% of portfolio). This preserves upside to successful rollout and limits theta bleed if adoption timelines slip.
• Volatility trade around near-term prints (30–60 day): sell short-dated strangle into inflated IV if implied vol jumps pre-announcement, but hedge with a small long further-dated call to protect vs a large upside gap. Target credit = 2–4% of notional; max loss protected via hedges.
• Hedge/Pair: if concerned about sector cyclicality, pair a LNTH long with a small short position in a generic radiotherapeutic exposure or broader small-cap biotech ETF to neutralize market beta; reduce net exposure by 20–40% until concrete throughput metrics emerge.